These observations along with our results suggest that p16− head and neck tumors that often harbor p53 mutations and exhibit increased angiogenesis could be more susceptible to vascular-targeted therapies such as VDAs and VEGF inhibitors. Here, TP53 is linked to head and neck neoplasm.